Androgens and Severe Insulin Resistance States: Basic and Clinical Aspects by Gambineri A. et al.
This item was downloaded from IRIS Università di Bologna (https://cris.unibo.it/)
When citing, please refer to the published version. 
This is the final peer-reviewed accepted manuscript of:  
Androgens and Severe Insulin Resistance States: Basic and Clinical Aspects 
Gambineri A, Zanotti L, Ibarra-Gasparini D, in  Hyperandrogenism in Women. Beyond Polycystic 
Ovary Syndrome. Front Horm Res. Basel, Karger, 2019, vol 53, pp 177–186 ( 
The final published version is available online at: 
https://doi.org/10.1159/000494911 
Rights / License: 
The terms and conditions for the reuse of this version of the manuscript are specified in the 
publishing policy. For all terms of use and more information see the publisher's website.   
Abstract
Hyperandrogenism with or without polycystic ovary syndrome can be sustained by an extreme form of 
insulin resistance (IR), and is thus a secondary form of hyperandrogenism, which may be due to a defect 
in insulin signal transduction or in the adipose tissue. Severe IR due to adipose tissue dysfunction is the 
most frequent form, which may be the result of a deficiency in the adipose tissue, that is, the lipodys-
trophies, or to the unrestrained accumulation of adipose tissue. These forms are in some cases produced 
by a single-gene defect. The diagnosis remains predominantly clinical by examining patients in their 
underwear and looking out for clinical hallmarks, supported by biochemical biomarkers. Gene screen-
ing is necessary to corroborate the diagnosis of some forms. Clinicians who deal with hyperandrogen-
ic disorders should be alerted to the forms that are secondary to severe IR, as they are not as uncommon 
as often imagined and frequently respond to tailored therapies. 
How to Biochemically Suspect a Severe Insulin Resistance State
Although no formal biochemical definition of severe insulin resistance (IR) exists, there 
is general consensus that the following conditions are indicators: a fasting insulin value 
above 20.9 µU/mL (150 pmol/L) and/or a peak insulin value on oral glucose tolerance 
testing above 209 µU/mL (1,500 pmol/L) when diabetes is absent and a body mass index 
(BMI) below 30 kg/m2; or an exogenous insulin requirement of above 3 U/kg of body 
weight per day when diabetes with absolute insulin deficiency is present in association 
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with a BMI below 30 kg/m2 [1]. However, in patients with partial β-cell compensation 
and/or with a BMI above 30 kg/m2, a diagnosis of severe IR is more difficult and should 
also include the clinical history and the presence of some physical signs (see the next sec-
tion), although high c-peptide levels can help in the diagnosis in insulin-treated patients 
[1] (Fig. 1).
Severe IR States: Clinical Aspects
IR is usually a condition of “partial” IR, which means that only some tissues are insulin 
resistant, particularly those involved in the metabolic effects of insulin (skeletal and car-
diac muscle and adipose tissue), whereas other tissues such as the pituitary, adrenal, ova-
ry, the skin and to some extent the liver, maintain a level of insulin sensitivity. In IR states, 
insulin is thus unable either to regulate glucose homeostasis at the level of adipocytes, 
skeletal and cardiac muscle or to suppress hepatic glucose production and lipolysis at the 
level of the adipose tissue. This then results in an increase in blood glucose and in circu-
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Fig. 1. Supportive clinical and biochemical aspects for severe insulin resistance (IR). BMI, body mass 
index; PCOS, polycystic ovary syndrome.
lating free fatty acid (FFA) levels [1]. On the other hand, before β-cell decompensation, 
the tissues that remain insulin-sensitive are exposed to the biological effects of exagger-
ated circulating insulin levels, which compensate IR.
Taken together, the above mechanisms lead to the most clinically important compo-
nent of the manifestations of severe IR states, which are acanthosis nigricans, a severe 
combined dyslipidemia (high triglycerides and low HDL-cholesterol levels), sometimes 
complicated by eruptive xanthomata and episodes of acute pancreatitis, an unusually se-
vere spectrum of fatty liver diseases, ranging from non-alcoholic fatty liver disease through 
steatoepatitis to advanced cirrhosis and rarely hepatocellular carcinoma, and early-onset 
hypertension and atherosclerotic diseases. In females, severe IR states are usually associ-
ated with clinical and/or biochemical hyperandrogenism and, possibly, with polycystic 
ovary syndrome (PCOS; Fig. 1).
Frequently there is also a lipodystropic phenotype that may be generalized or, more 
frequently, partial. Interestingly, acanthosis nigricans and, in females, hyperandrogenism 
with or without PCOS, accompany almost all the forms of severe IR states, including the 
forms due to insulin receptor (INSR) defects. In the latter forms, however, there is no dys-
lipidemia, fatty liver disease, or early atherosclerosis, thus suggesting that some in vivo 
effects of insulin are not only INSR mediated [1].
Acanthosis nigricans can be considered the clinical marker of severe IR and of all the 
IR states in general. It is characterized by thickened, brown, velvety skin in flexturs, often 
associated with skin tags or acrochordons. In the most severe cases, there may be perioral, 
periocular and buccal regions, even on planar surfaces (Fig. 1).
Severe IR States: How Many Causes Do We Actually Know?
For many years, the term “HAIR-AN” has been commonly used to identify the association 
between hyperandrogenism, severe IR and acanthosis nigricans. However, this is an im-
precise, simplistic and overlapping definition of an extremely heterogeneous number of 
different forms of severe IR states associated with hyperandrogenism. Over time this term 
has thus been abandoned and replaced by mechanism-based classifications. Severe IR 
states are now usually classified in 2 categories: those disorders in which there is a pri-
mary defect in insulin signal transduction (Primary IR) and those in which severe IR is a 
consequence of adipose tissue dysfunction [2].
Primary IR can be then subdivided into the forms in which there is a defect at the lev-
el of the INSR, and the forms in which there is a signaling defect that is limited either to 
only some parts of the postreceptor signal transduction pathway or to some tissues [2]. 
The INSR spectrum of disorders includes those due to INSR autoantibodies and INSR 
mutations [2]. INSR autoantibodies act in various ways including direct binding-site in-
activation, accelerated receptor degradation, or inhibition of conformational changes 
within the receptor after binding. Only a few mutations have been discovered that are in-
volved in the defect of the signalling pathway downstream of the INSR. These consist of 
a non-functional mutation in AKT2 encoding a critical serine/threonine kinase and a 
non-sense mutation in AS160 encoding for a GTPase-activating protein that forms the 
link between insulin signalling and glucose uptake by the GLUT4 transporters [2].
Adipose tissue dysfunction is the most frequent form of severe IR, which can be subdi-
vided into a group with lipodystrophy, in which there is a deficiency in subcutaneous adi-
pose tissue, and into another group in which the defect comprises an unrestrained accu-
mulation of adipose tissue; it is therefore associated with severe obesity commonly due to 
hyperphagia [2]. Lipodystrophy can be generalized or partial, congenital or acquired [2].
A combination of linkage analysis and candidate gene screening has led to the identi-
fication of a list of genes associated with congenital lipodystrophies, which encode essen-
tial proteins for normal fat tissue development and/or function in humans. The genes 
implicated in the pathogenesis of congenital lipodystrophies can be categorized as being 
primarily involved in: the transcriptional regulation of adipocyte differentiation; fatty acid 
uptake; triacylglycerol (TAG) synthesis; and lipid droplet formation [3]. The genes in-
volved in the alteration of adipocyte differentiation are the peroxisome proliferator acti-
vated receptor y-PPARG, a member of the nuclear hormone receptor superfamily; LMNA, 
an encoding lamin A/C, which is a nuclear envelope protein with many cellular roles in-
cluding chromatin and transcription factor binding and organization of the nuclear mem-
brane and cytoskeleton; zinc metallopeptidase STE24 homologue-ZMPSTE24, which en-
codes a metalloproteinase essential for the processing of prelamin A to mature lamin A 
protein; and AKT2, a Ser/Thr kinase that is critical in the insulin-signaling cascade re-
quired for adipogenesis [4].
The 2 genes involved in the alteration in fatty acid uptake by adipocytes are (i) CAV1, 
which encodes caveolin-1; and (ii) PTRF, which encodes polymerase 1 and the transcript 
release factor, also called cavin-1, which are proteins that mediate caveolae formation or 
stabilization. Caveolae are specialised plasma membrane microdomains involved in fatty 
acid uptake, INSR recycling and GLUT4 organisation in adipocytes. The loss of these pro-
teins likely disrupts adipose tissue function, both through impairment in the fatty acid 
uptake, and thus TAG synthesis, and, more speculatively, through the loss of insulin sig-
nalling into the cell.
AGPAT2 is the gene involved in the alteration in TAG synthesis, encoding the enzyme 
acylglycerol 3-phosphate O-acyltransferase 2, which is located in the endoplasmic reticu-
lum and catalyses the conversion of lysophosphatidic acid to phosphatidic acid, a key step 
in the synthesis of triglycerides and glycerolphospholipids from glycerol-3-phosphate. 
Finally, the genes behind the alteration in lipid droplet formation are Berardinelli-Seip 
congenital lipodistrophy-BSCL2 or seipin, cell death-inducing DFFA-like effector C or 
CIDED, and Perilipin-PLIN1, each of which resides on the surface of the lipid droplet and 
regulates triglyceride mobilization.
Mutations in another 2 genes associated with inherited forms of lipodystrophies have 
recently been described: polymerase delta 1 or hormone-sensitive lipase [2, 5, 6].
Mutations in BSCL2, AGPAT2, CAV1, and PTRF cause congenital generalized lipo-
dystrophies that are characterized by the nearly complete absence of subcutaneous adi-
pose tissue and consequently a generalized muscular appearance that is easily recognized 
at birth. On the other hand, mutations in LMNA, PPARG, PLIN1, CIDEC, ZMPSTE24, 
AKT2, polymerase delta 1 and hormone-sensitive lipase cause congenital partial lipodys-
trophies, which are always characterized by a loss of fat in the arms, legs, and buttocks, as 
well as loss of fat that typically starts during puberty and gradually gets worse [7]. The 
most frequent form of congenital partial lipodystrophy is due to missense mutations at 
the level of the LMNA gene, known as familial partial lipodystrophy (FPLD) type 2. FPLD 
type 2 is phenotypically characterized by the loss of fat in arms more prominently in the 
forearms and calves than in the upper arms and thighs, a variable and progressive loss of 
subcutaneous fat from the chest, and an abnormal gain of fat in the face and neck and 
intra-abdominal region.
Another quite frequently inherited variety of partial lipodystrophy is FPLD type 1 or 
Köbberling syndrome, where a polygenic or oligogenic pathogenesis has been suggested. 
The phenotype starts in childhood, and worsens with menopause and weight gain. De-
spite the apparent lipoatrophy in the lower limbs, which can be variable in the upper 
limbs, patients are frequently obese and have a notable accumulation of abdominal fat 
(including subcutaneous fat), and thus are usually diagnosed with android obesity [8, 9].
The acquired forms of lipodystrophies are phenotypically characterized by a defect in 
adipose tissue that affects the face, neck, thorax (in the partial forms), and also arms, legs, 
and sometimes the palms and soles (in the generalized form), but the abdomen is pre-
served and not in excess. In the partial forms, there may be a compensatory accumulation 
of adipose tissue in the glutea and legs. In acquired lipodystrophy, the fat loss may appear 
at any age depending on the time of appearance of the primary cause.
Clinicians who manage hyperandrogenism in females should be alerted to these forms 
as they are secondary to severe IR states and, therefore, usually benefit from tailored ther-
apies.
Basic Mechanisms for the Association between Severe IR States and 
Hyperandrogenism
Insulin can produce hyperandrogenism in females with severe IR states by acting at the 
level of different tissues, which trigger the synthesis and peripheral actions of androgens 
(Table 1). Insulin enhances the pituitary response of LH to GnRH, finally stimulating 
ovarian LH-mediated androgen production [2]. At the ovarian level, insulin upregulates 
LH receptors, as well as type 1 IGF and hybrid insulin/type 1 IGF receptors, thus increas-
ing the production of androgens, estrogens and progesterone by the granulosa and thecal 
cells. In addition, insulin directly increases ovarian androgen synthesis by stimulating cy-
tochrome P450c17α activity, a key enzyme in the biosynthesis of androgens, which has 
both 17α-hydroxylase and 17,20-lyase activities [2]. Insulin also increases IGF-1 expres-
sion and downregulates IGF binding protein production in the ovary, leading to a local 
increase in free IGF-1 and IGF-2 levels that act on thecal cells to enhance androgen pro-
duction [2]. Insulin may also stimulate adrenal androgen production through a direct ef-
fect on cytochrome P450c17α and/or an increased sensitivity of adrenal to ACTH.
At the hepatic level, insulin inhibits the synthesis of the sex hormone-binding globulin, 
thereby increasing the amount of free androgens and consequently the peripheral andro-
gen action. Insulin also inhibits the synthesis of IGF binding protein 1, leading to the in-
creased bioavailability of IGF-1 and -2 [2]. Overall, these effects lead to an increased syn-
thesis of androgens by the adrenal and ovarian thecal cells as well as an increased periph-
eral bioavailability of androgens and, therefore, to a condition of hyperandrogenism.
Finally, at the ovarian level, insulin directly acts on the granulosa cells of small follicles 
leading to premature granulosa terminal differentiation and the arrest of follicular growth. 
This effect in association with the insulin-mediated reduction in ovarian efficacy of go-
nadotropins and the increase in intraovarian androgen levels may cause premature fol-
licular atresia and antral follicular arrest. This can subsequently lead to the collapse of 
small antral follicles into the ovarian stroma, leading to stromal hypertrophy and the pro-
motion of ovarian atresia, finally leading to the development of polycystic ovarian mor-
phology and anovulation [2].
Androgen excess, on the other hand, can aggravate IR through key effects on some tar-
get tissues. In females, androgens impair adipogenesis by inhibiting the proliferation and 
differentiation of mesenchymal stem cells and preadipocytes [10] with a compensatory 
adipocyte hypertrophy, which could induce adipocyte dysfunction that manifests itself in 
Table 1. Basic mechanisms for the association between severe insulin resistance states and hyperan-
drogenism in females
Effect of insulin excess Effect of androgen excess
Pituitary Adipose tissue
– Enhances the effect of GnRH on LH – Induces hypertrophy
– Decreases insulin sensitivity
– Increases visceral lipid accumulation
Ovary Skeletal muscle
– Acts synergistically with LH to stimulate steroidogenesis – Decreases insulin sensitivity
– Upregulates LH receptors
– Directly stimulates steroidogenesis
– Upregulates type 1 IGF receptors or hybrid insulin/type 1
IGF receptors
– Inhibits SHBG production
– Inhibits IGFBP-1 production
– Promotes polycystic ovarian morphology and anovulation
Adrenal
– Stimulates androgen production
Liver
– Inhibits SHBG production
– Inhibits IGFBP-1 production
IR, intracellular stress and inflammation [11]. In fact, hypertrophic adipose tissue is insu-
lin resistant, produces a high amount of FFAs, and secretes high levels of pro-inflamma-
tory cytokines, particularly TNF-alpha and IL-6 and low levels of adiponectin [11]. An-
drogens also have a direct effect on adipose insulin sensitivity. In particular, testosterone 
(T) directly induces IR in female subcutaneous adipocytes in vitro, and inhibits insulin-
stimulated glucose uptake by impairing the phosphorylation of protein kinase C via an
androgen receptor-mediated mechanism [12]. In addition, an enhanced lipogenesis has
been found in the omental adipocytes of obese hyperandrogenic females compared with
obese non-hyperandrogenic controls [13, 14]. This thus highlights the possible role of an-
drogens in promoting visceral adipose lipid accumulation in women if such androgens
are at supraphysiological concentrations.
At the level of the skeletal muscle, if androgens in females are at supraphysiological 
levels, they impair insulin sensitivity by interfering with insulin signalling and by induc-
ing changes in the myocyte morphology. These changes can include, for example, a de-
crease in insulin sensitive type I fibres, an increase in less sensitive type IIb fibres, a de-
crease in capillarization, and the inhibition of glycogen synthase expression and activity 
[15]. Therefore, hyperandrogenism in females aggravates IR by directly affecting both the 
adipose tissue and the skeletal muscle.
All these data support the presence of a significant bidirectional interaction between 
IR and hyperandrogenism in females.
Clinical Studies Highlighting the Association between Hyperandrogenism and 
Severe IR States
The association of hyperandrogenism with severe IR states has been described only in a 
few studies. One study highlighted the presence of oligomenorrhea and hyperandrogen-
ism in 7 females affected by INSR defects [16]. Another described ovarian hyperandrogen-
ism in 3 members of a family of carriers of a non-functional, heterozygous mutation in 
AKT2 [17]. Other studies have described the association of oligo-amenorrhea, hirsutism, 
and hyperandrogenemia with FPLD2 [18–21].
In our experience, PCOS secondary to partial congenital lipodystrophy is more com-
mon than is thought. In fact, referrals to our centre in the last 10 years have shown a prev-
alence of 1% of PCOS secondary to partial congenital lipodystrophy. Of the 1,200 patients 
visiting our out-patient clinic for symptoms of PCOS (oligo-amenorrhea, hirsutism, in-
fertility), we found 18 cases with a partial lipodystrophic phenotype. Of these, twelve cas-
es were affected by a partial congenital lipodystrophy. In detail, nine were affected by a 
heterozygous missense mutation in gene LMNA, one case was affected by a heterozygous 
missense mutation in gene PPARG, and 2 cases by a heterozygous missense mutation in 
gene PLIN1. No substantial clinical differences among the different forms of partial con-
genital lipodystrophy were observed. The clinical characteristics of these patients are re-
ported in Table 2.
Therapeutic Strategies for Hyperandrogenism Secondary to Severe IR
The identification of a form of hyperandrogenism secondary to severe IR is important in 
clinical practice because it frequently benefits from tailored therapies, including specific 
dietary management or caloric restriction in general [22], as well as specific insulin sensi-
tizers, such as thiazolidinediones [18], and in some cases, metreleptin therapy [23, 24]. 
Dietary management is the most critical element of treating severe IR because it can have 
a dramatic beneficial effect on metabolic derangement and, therefore, on hyperandrogen-
ism. This is particularly important in lipodystrophy where, however, the apparent lean-
ness of patients frequently results in a failure of caregivers to place sufficient emphasis on 
dietary modifications. On the other hand, the use of low-fat, energy-balanced or some-
times hypocaloric diets in lipodystrophic patients is of great benefit because of the “offload” 
of adipose tissue. However, dietary management is particularly difficult in lipodystrophy 
because both absolute and relative leptin deficiencies, in generalized and partial lipodys-
trophy, respectively, lead to hyperphagia [25]. Given the importance of restricting energy 
intake, particularly in patients with unrestrained accumulation of adipose tissue, other 
weight loss therapies, including glucagon-like peptide-1 agonists and appetite suppres-
sants, can have clinical benefits, and bariatric surgery may perhaps be helpful in severe 
cases [1].
Insulin-sensitizing agents also play an important role in the management of severe IR 
states; however, metformin is often ineffective or insufficiently effective and requires the 
addition of thiazolidinediones, which are peroxisome proliferator-activated receptor γ 
agonists. Thiazolidinediones may be beneficial not only due to the systemic insulin-sen-
Table 2. Clinical and biochemical characteristics of a group of patients with PCOS secondary to severe insulin resistance 
associated with lipodystrophy visiting our out-patient clinic for the first time
Patient Mutation Main complaint Age,
years
BMI, 
kg/m2
T,
ng/m
FGlu,
mg/day
FIns,
μU/mL
H AN High
Tg
NAFDL DM HBP CV
events
PCOm
1 LMNA Hirsutism 21 26 0.7 72 21.0 Y Y Y N N N N Y
2 LMNA Amenorrhea 15 25 1.2 80 33.3 Y Y Y Y N N N Y
3 LMNA Amenorrhea 22 23 0.3 83 26.8 Y Y Y N N N N N
4 LMNA Hirsutism 35 22 0.2 95 21.3 Y Y Y N N N N Y
5 LMNA Hirsutism 62 24 0.6 100 16.2 Y Y Y Y Y Y Y N
6 LMNA Hirsutism 59 26 0.8 101 94.0 Y Y Y Y Y Y Y Y
7 LMNA Hirsutism 31 26 0.5 92 30.2 Y Y Y Y N N N Y
8 LMNA Amenorrhea 34 24 0.2 74 20.9 Y Y Y Y N N N Y
9 LMNA Hirsutism 16 22 0.8 83 21.6 Y Y Y N N N N Y
10 PLIN1 Amenorrhea 33 37 0.3 106 39.0 Y Y N Y N N N Y
11 PLIN1 Hirsutism 22 23 0.3 90 33.0 Y Y Y Y Y N N Y
12 PPARy Oligomenorrhea 31 25 1.5 91 88.2 N Y Y Y N Y N Y
14 Unknown Amenorrhea 19 47 1.0 83 82.0 Y Y N Y N N N Y
15 Unknown Amenorrhea 23 23 0.2 256 15.4 Y Y Y Y Y N N Y
BMI, body mass index; T, testosterone; FGlu, fasting glucose; FIns, fasting insulin; H, hirsutism; AN, acanthosis nigricans; Tg, triglycerides; NAFDL, non-
alcoholic fatty liver disease; DM, diabetes; HBP, hypertension; CV, cardiovascular; PCOm, polycystic ovarian morphology; Y, yes; N, no.
sitizing action and consequent reduction of hyperinsulinemia but also due to a direct in-
sulin-independent effect on the ovary with a consequent decrease in thecal cell steroido-
genesis [26]. In addition, they are of particular benefit in partial lipodystrophy because 
they stimulate adipogenesis, thus providing extra fat depots [18].
In patients with lipodystrophy and low levels of serum leptin, recombinant leptin ther-
apy may dramatically improve glycaemic control, dyslipidemia, and hepatic lipid accu-
mulation [27] and also to some extent resolve menstrual dysfunctions and hyperan-
drogenism [23]. The patients that benefit most from this therapy are those with extreme-
ly low or undetectable serum leptin levels. Leptin replacement should therefore always be 
considered in patients with generalised lipodystrophy.
Conclusions
Clinicians who deal with hyperandrogenic disorders should be alerted to the forms that 
are secondary to severe IR states as they are not as uncommon as may be expected and 
may respond to tailored therapies. The diagnosis of these forms remains predominantly 
clinical by examining patients in their underwear, looking out for clinical hallmarks, and 
supported by biochemical biomarkers. Gene screening is necessary to corroborate the di-
agnosis of some of these forms but must be performed at the end of the diagnostic path. 
Further studies are needed to detail the phenotypic features, diagnostic procedures, and 
potential therapeutic approaches to these secondary forms of hyperandrogenic states.
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